Paid Clinical Trials Cincinnati
Discover 1,280 paid clinical trials in Cincinnati. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)
Sponsor:
GB002, Inc.
Location:
Code:
NCT05934526
Conditions
Pulmonary Arterial Hypertension
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
Placebo
Seralutinib
Generic Dry Powder Inhaler
Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy
Sponsor:
Biohaven Therapeutics Ltd.
Location:
Code:
NCT06309966
Conditions
Focal Epilepsy
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
BHV-7000
Placebo
Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
Sponsor:
Jazz Pharmaceuticals
Location:
Code:
NCT05734066
Conditions
Refractory Ewing Sarcoma
Relapsed Ewing Sarcoma
Ewing Sarcoma
Eligibility Criteria
Sex: All
Age: 2 - 30
Healthy Volunteers: Not accepted
Interventions
Lurbinectedin
Epilepsy Journey-An Executive Functioning Intervention for Teens With Epilepsy
Sponsor:
Children's Hospital Medical Center, Cincinnati
Location:
Code:
NCT06608966
Conditions
Epilepsy in Children
Executive Dysfunction
Eligibility Criteria
Sex: All
Age: 13 - 17
Healthy Volunteers: Not accepted
Interventions
Epilepsy Journey web-based modules
Telehealth with a therapist
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Sponsor:
AstraZeneca
Location:
Code:
NCT06283966
Conditions
COPD (Chronic Obstructive Pulmonary Disease)
Eligibility Criteria
Sex: All
Age: 40 - 70+
Healthy Volunteers: Not accepted
Interventions
BGF MDI 320/14.4/9.6 μg
GFF MDI 14.4/9.6 μg
A Study to Investigate the Effect on Lung Function of BDA Formulated With a New Propellant (HFO) Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
Sponsor:
AstraZeneca
Location:
Code:
NCT06502366
Conditions
Asthma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
BDA MDI HFO 160/180 μg
BDA MDI HFA 160/180 μg
Placebo MDI HFA
Harmony TPV Post-Approval Study
Sponsor:
Medtronic Cardiovascular
Location:
Code:
NCT05077774
Conditions
Congenital Heart Disease
Tetrology of Fallot
RVOT Anomaly
Pulmonary Regurgitation
Eligibility Criteria
Sex: All
Age: 0 - 70+
Healthy Volunteers: Not accepted
Interventions
Harmony TPV System
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor:
NRG Oncology
Location:
Code:
NCT05879926
Conditions
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18 - 60
Healthy Volunteers: Not accepted
Interventions
Ovarian Function Suppression + Aromatase Inhibitor
Adjuvant Chemotherapy + Ovarian Function Suppression
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
Sponsor:
Dermavant Sciences, Inc.
Location:
Code:
NCT05172726
Conditions
Plaque Psoriasis
Eligibility Criteria
Sex: All
Age: 2 - 17
Healthy Volunteers: Not accepted
Interventions
tapinarof cream, 1%
A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
Sponsor:
Jubilant Therapeutics Inc.
Location:
Code:
NCT05268666
Conditions
Locally Advanced Solid Tumor
Metastatic Solid Tumor
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
JBI-802